Loading
Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.
Replication restricted by the E2F-1 promoter to RB-deficient cells; expresses GM-CSF. BOND-003 cohort C: CR 75.2%, 24-month CR 41.8%, no grade 3+ treatment-related events. Rolling BLA under way; full submission expected Q4 2026. Also tested in BCG-naive (CORE-008) and intermediate-risk (PIVOT-006) NMIBC. CG Oncology.
Conditionally replicating adenovirus lyses RB-pathway-defective tumour cells and secretes GM-CSF to recruit antigen-presenting cells.
1.Intravesical instillation after a surfactant (DDM) to loosen the urothelial barrier
Compare all products across the US, EU, UK, Japan, China and Australia →
Rolling BLA initiated; completion expected Q4 2026 source
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Bladder spasm | 20% | - |
| Urinary urgency | 18% | - |
| Grade 3+ treatment-related | - | 0% |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cretostimogene grenadenorepvec" OR ABSTRACT:"Cretostimogene grenadenorepvec" OR TITLE:"CG0070" OR ABSTRACT:"CG0070") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cretostimogene grenadenorepvec, not a curated reading list.
Shares BCG-unresponsive, Oncolytic viruses that make interleukin-12 only inside the tumour, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares BCG-unresponsive, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.